Merkliste
Die Merkliste ist leer.
Der Warenkorb ist leer.
Kostenloser Versand möglich
Kostenloser Versand möglich
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
Digital Therapeutics
ISBN/GTIN

Digital Therapeutics

Strategic, Scientific, Developmental, and Regulatory Aspects
E-BookEPUBE-Book
Verkaufsrang84255inMathematik
CHF308.50

Beschreibung

Digital Therapeutics: Scientific, Statistical, Clinical, and Regulatory Aspects is an unparalleled summary of the current scientific, statistical, developmental, and regulatory aspects of DTx which is poised to become the fastest growing area of the biopharmaceutical and digital medicine product development.
Weitere Beschreibungen

Details

Weitere ISBN/GTIN9781000799378
ProduktartE-Book
EinbandE-Book
FormatEPUB
Erscheinungsdatum06.12.2022
Auflage22001 A. 1. Auflage
Seiten462 Seiten
SpracheEnglisch
Dateigrösse8517 Kbytes
Illustrationen105 farbige Abbildungen, 57 schwarz-weiße Fotos, 48 farbige Zeichn., 17 schwarz-weiße Tabellen
Artikel-Nr.20890198
KatalogVC
Datenquelle-Nr.4076424
Weitere Details

Bewertungen

Autor

Dr. Oleksandr Sverdlov is Neuroscience Disease Area Lead Statistician in early clinical development at Novartis. He received B.Sc. in Applied Mathematics from V.N. Karazin Kharkiv National University, Ukraine, M.Sc. in Statistics from University of Maryland, Baltimore County (UMBC), and Ph.D. in Information Technology with Concentration in Statistical Science from George Mason University. He has been actively involved in methodological research and applications of innovative statistical approaches in drug development. He is the editor of a monograph "Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects" (CRC Press/Chapman & Hall, 2015) and a co-author of a book "Mathematical and Statistical Skills in the Biopharmaceutical Industry: A Pragmatic Approach" (CRC Press/Chapman & Hall, 2019). His most recent work involves design and analysis of proof-of-endpoint clinical studies evaluating novel digital technologies.

Joris van Dam is a Digital Health Intrapreneur, helping organizations deliver upon the promise of digital health technologies to transform the experience and treatment outcomes of the patients we collectively serve. For the past several years, Joris has led the Digital Therapeutics research program at the Novartis Institutes of Biomedical Research in Cambridge, MA. In the 10+ years before that, Joris worked on a wide variety of Digital Health solutions improving the clinical treatment and the clinical research experience of patients and providers in the U.S., Europe, India, and Africa. Joris received a Ph.D. in Computer Science / Artificial Intelligence from the University of Amsterdam in 1998, after which he spent several years in consulting and program management before recognizing the promise and the urgency of digital health solutions to improve the health of our nations.